Performance of the Project. Each Party shall carry out the research and tasks which it is specified to perform in the project plan set out in Schedule 2, and provide the human resources, materials, facilities and equipment that are designated to be provided by it in the project plan, in each case in a timely manner, in accordance with good accepted research practice and all applicable laws, and with due regard for the health and safety of those involved in the Project.
Performance of the Project. The Funding Recipient must, and must ensure that its Personnel must:
Performance of the Project. 2.1 At the commencement of the PROJECT, both PARTIES hereby expressly acknowledge that both PARTIES are uncertain whether the PARTIES will complete the PROJECT and achieve the results of the PROJECT.
Performance of the Project. 4.1 During the Term of this Agreement, Emory agrees:
Performance of the Project. The concrete content of the contribution of each Party in the Project is described in detail in the Proposal known by all Parties and attached to this document (Exhibit 2). The Parties will collaborate in good faith in order to implement the Project as set out in the Proposal. Each Party will use its best endeavours to carry out the Project in a timely and efficient manner. Each Party shall perform the tasks allotted to it in the Proposal and provide the human resources, materials, facilities and equipment that are designated as its responsibility in the Proposal. The Parties will ensure to exchange, and where necessary request, all necessary information without impairing any obligation of confidentiality. No warranty regarding outcome of scientific research. Although each of the Parties will use its best endeavours to carry out the Project in accordance with the Proposal, no Party undertakes that any research will lead to any particular result, nor does it guarantee a successful outcome to the Project.
Performance of the Project. 3.1. Each Party agrees to:
Performance of the Project. 3.1 The Parties shall provide each other with all of the information needed for the performance of the Project following prior coordination. Any documents, objects or other resources which one of the Parties needs in order to perform the work shall be provided by the other Party as far as possible. They shall be used exclusively for the purposes of performing the Project. STELLAR will in particular make available to BIG within a time period of thirty (30) days from the Effective Date or in case of the last bullet point immediately after production of the data and results: · a report including all information about the Improved KLHsu Production Method and/or all information useful or needed to obtain the Improved KLHsu Production Method including confidential manufacturing and analytical protocols, process development plans as well as all experimental data that support the expectation of the 60% yield (but not less than a 50% yield) of the purified KLHsu, · all limpets ((Megathura crenulata) required for production of ASP KLH for the Project, · all ASP KLH required for BIG to perform the Project, · the Drug Master File (DMF) on STELLAR´s current KLHsu, · all analytical and preclinical data and study results produced by STELLAR in the development, evaluation and validation of the Improved KLHsu Production Method and any comparability testing of STELLAR’s KLHsu. BIG will in particular make available to STELLAR: • all KLHsu material produced from STELLAR ASP KLH initially provided pursuant to paragraph 3.1 but not specifically required to perform the Project, • all preclinical data and study results produced by BIG in the development, evaluation and validation of the Improved KLHsu Production Method and comparability testing of STELLAR’s KLHsu which BIG is allowed to forward to STELLAR and which is necessary for STELLAR .
Performance of the Project. Patheon will perform the Project in compliance with the terms and conditions of this Agreement, AcelRx’s instructions, and all applicable laws and regulations. Patheon will perform the Project in accordance with the timeline that will be established by the combined Patheon-AcelRx Project team. This timeline may be modified by mutual agreement of the parties. With respect to the Dedicated Equipment that will be transferred from Patheon Canada’s facilities to the Facility, AcelRx will be responsible for the packaging and transport of the Dedicated Equipment to the Facility. Patheon Canada will allow and support access to the Dedicated Equipment by the AcelRx packaging/transport contractor(s). AcelRx will bear the risk of loss of or damage to the Dedicated Equipment during transit to the Facility, and will obtain insurance covering such risk of loss or damage while in transit. AcelRx will be responsible for obtaining appropriate import and related documentation for the transport of the Dedicated Equipment. Once delivered to the Facility, Patheon will be responsible for the installation of the Dedicated Equipment and for any risk of damage thereof.
Performance of the Project. At present, the parties contemplate that the Project will be conducted using two separate developmental approaches, one in the yeast system and one in the bovine system (each an "Approach"). The parties shall agree upon the development plan for the Project ("Project Plan") in writing no later than thirty (30) days after the execution of this Agreement. The Project Plan shall set forth for both Approaches: (i) the parties' strategies, plans, activities and schedules with regard to research, development, pre-clinical, pre-regulatory, scale-up and manufacturing development; and (ii) the parties' respective responsibilities for performing the Project. The Project Plan shall be reviewed at least once per calendar quarter by the management of each party and at least once every six (6) months by the Board of Directors of each party and may be amended from time to time during the Term (as defined herein) by mutual agreement of the parties. Subject to the terms and conditions of this Agreement, each party shall use its commercially reasonable efforts to perform the Project in accordance with the Project Plan. The parties' respective obligations to perform each Approach shall terminate when the Bioequivalence Milestone has been reached for such Approach unless the parties agree to terminate the Project or such Approach at an earlier date; provided, however, in the event that the parties mutually agree to terminate an Approach, Collagen shall, subject to Article III, be granted the license set forth in Section 3.1 to any Recombinant Technology developed by such Approach prior to and up to the termination of such Approach. Notwithstanding anything herein to the contrary, upon mutually agreeable terms, Collagen and Technologies may agree to: (i) expand their collaboration beyond the Project so as to include research, development, pre-clinical, pre-regulatory, scale-up or manufacturing development relating to designer collagen materials or technologies other than Recombinant Technology; and/or (ii) continue their collaboration with respect to Recombinant Technology after the Bioequivalence Milestone has been reached in either one or both Approaches.
Performance of the Project. The Recipient must perform the Project in accordance with the terms of this Agreement, the timeframes specified in the Schedule and all applicable laws. Agreement Period This Agreement commences on the Commencement Date and ends when the Recipient has performed its obligations under this Agreement to the DNP’s satisfaction or this Agreement is otherwise terminated under clause 19.
